HENRIQUEZ PARTNERS EXHIBITS AT THE VENICE BIENNALE "SYMPLASMA"
Throughout our existence, humans have taken inspiration from the natural world, using technology to mimic what nature has created through millions of years of evolution. In this era of environmental crisis, where our actions directly threaten both the natural world and our own existence, we must also look to nature to build structures and cities that actively address sustainability pragmatically and express it poetically.
Drawing from the 2025 Biennale theme " Intelli/Gens", Symplasma is inspired by the rare and ancient Hexactinellid sea sponge – its resilience, function and ability to survive and continue its integral role in our ocean's ecosystem. Glass sea sponge habitats pertain to both Vancouver, where reefs currently adorn the coast of North America's Pacific Northwest, and to Venice during the Paleozoic period around the ancient Tethys Sea.
By merging the biological wisdom of glass sea sponges with the historical lessons embedded in Venice's urban fabric, Symplasma envisions new paradigms of resilience: structures that do not resist nature but instead move with it, harnessing energy from the sun, wind, and earth as they adapt. In doing so, it reframes Venice as both a cautionary tale and a beacon of possibility—an evolving city that, like Calvino's imagined worlds, continues to reinvent itself in response to forces beyond its control.
Henriquez, in collaboration with ARUP, explore a climate crisis narrative that takes inspiration from the natural, historical and cultural surroundings. The exhibition features monumentally scaled, 3-D printed glass sea sponge sculptures, visual interventions inspired by Canaletto's paintings, and a proposal for Vancouver's first 'supertall' towers.
The Vancouver towers take their inspiration aesthetically and functionally from the glass sea sponge by incorporating structural and sustainable strategies that minimizes their carbon footprint and achieves net zero carbon in its operation. A continuous diagrid structure allows the building to address lateral and gravity loads simultaneously and geoexchange, photovoltaics, and air source heat exchange eliminate the need for carbon intensive energy sources.
Complementing the Vancouver project is an allegorical project in Venice which proposes to introduce new constructed metaphorical 'glass sponges' or 'Sustainability Machines', to Venice, structures that use nature to sustainably harness, store and distribute energy and are represented in the context of Canaletto's timeless paintings.
Venice has been a muse for generations of artists and thinkers - suggesting a city suspended between material reality and dreamlike possibility, a space where history, water, and time intertwine. It also has a history of bold responses to crisis: the great plague churches, such as Santa Maria della Salute, were acts of both spiritual devotion and architectural ingenuity, built as symbols of resilience in the face of catastrophe. Today, as both cities confront the existential threat of climate change, these historical responses take on new meaning. The climate crisis, like the plagues of the past, demands a reckoning, not just with survival, but with transformation.
The exhibition is now on display at the European Cultural Centre exhibition TIME SPACE EXISTENCE, at Palazzo Bembo near the Rialto Bridge as part of the Venice Biennale, May 10—November 23, 2025.
About Henriquez Partners:
Henriquez Partners Architects is a Canadian architectural studio, based in Vancouver, British Columbia. Led by Gregory Henriquez and his belief that architecture has the potential to be a poetic expression of social justice, the studio seeks to re-examine the role of ethics, activism, and critical commentary in architectural practice. Henriquez Partners seeks to re-establish the role of the architect as one of leadership in the creation of the collective space that form the fabric of our daily lives and communities.
Henriquez is now best known for inclusive zoning within mixed-use projects. The Woodward's redevelopment, completed in 2011, in Vancouver's Downtown Eastside, remains unprecedented in Canada due to its scale, humanitarian aspirations and complexity. Since then, the studio's socially, culturally and environmentally sustainable projects continue to have a major impact on shaping local communities. Current large-scale mixed-use projects include the 5.0 million ft² Oakridge Redevelopment in Vancouver, in addition to three major projects in Toronto: 1.0 million ft² Mirvish Village in Toronto, and 800,000 ft² affordable housing with CreateTO at 5207 Dundas St W - both currently under construction, as well as 1.0 million ft² CreateTO & Co-op Federation of Toronto.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
a day ago
- Winnipeg Free Press
Navigating the unknown
Among the many technical terms from fields such as neuroscience, artificial intelligence, applied mathematics and genetics found in this fascinating new book by bestselling Canadian science writer/distance runner/physicist Alex Hutchinson, the reader discovers 'prediction error.' It's a term that comes from studies of how the brain makes sense of the impressions presented to it by the senses. The brain doesn't simply receive sensory data; rather, it continually makes predictions based on partial sense data and feeds these back to the senses. When we get lost, the predictions we make tend to be errors. We also carry a variant of the gene DRD4 that gives us a happy endorphin boost when our rate of prediction error declines. That genetic variant, Hutchinson writes, emerged 40-50,000 years ago, 'right around the time when our ancestors began their long, multi-pronged march to the farthest corners of the globe. It was a march, the findings hinted, spurred in part by dopamine.' Associated Press files Despite the book's title, Alex Hutchinson's latest is about much more than investigating far-flung and remote corners of our planet. Appropriately enough, The Explorer's Gene will be picked up by many readers as a result of a prediction error. Judging by the title and the historic mountaineering photo on the cover, readers may assume the book is a story of outdoor adventure. So it may come as a surprise that it's packed with discussions of experiments involving social-science questionnaires, rats in cages or brain imaging. Exploration, in Hutchinson's context, can mean striding off into the unknown, conducting scientific research or even varying your restaurant selections. Should you always order from the pizza parlour you like, knowing from experience that you'll enjoy it? Or should you 'explore' the restaurant scene in case a new, better place has opened up? According to Hutchinson, the science says 'try that new joint now and then.' Hutchinson, who has a master's degree in journalism from Cornell University and a PhD in physics from the University of Cambridge, drew on his experience with Canada's national distance running team to write the bestseller Endure, on the science of endurance. Hutchinson cites Swedish speedskater Nils van der Poel as an example of the benefits of experimentation. The skater had done reasonably well with the standard approach to training, but after the 2018 Olympics tried an unheard-of training regimen that led to Olympic gold in Beijing in 2022 and world records. Supplied photo Hutchinson is a science writer, long-distance runner and physicist. Weekly A weekly look at what's happening in Winnipeg's arts and entertainment scene. Each chapter begins with a capsule illustration of an aspect of exploration, exemplified in incidents such as Alexander Mackenzie's journey to the Arctic Ocean in the 18th century or the Polynesian voyages that settled the Pacific Ocean. One story, about a six-year-old boy who got lost in the mountains of Oregon and found his way home on his own, introduces a discussion of free childhood play as a form of exploration and the worrisome consequences of a decline in such exploration in a wired, media-fed culture. Another topic may be of special interest to readers with a lot of mileage on their traveling shoes. It's called the 'explore-exploit' dilemma. Generally speaking, we explore when we're young and have time to make mistakes and try again. When we're older we 'exploit' our existing knowledge, living off skills acquired earlier. But that doesn't mean we should give up exploring altogether. In fact, Hutchinson argues that continuing to explore helps keep people physically and mentally healthy as they age. So even if you feel too old to learn about algorithms and game theory, and even if your explorations are mostly carried out through a screen, adding The Explorer's Gene to your bookcase may help you navigate the seas of advancing age as you sail toward the final discovery. Bob Armstrong is a Winnipeg novelist who writes about his explorations on Substack @wanderingwriterbobarmstrong. The Explorer's Gene
Winnipeg Free Press
a day ago
- Winnipeg Free Press
Bond between brain docs led to crucial breakthroughs
Since the early 1990s, the charitable organization Historica Canada has produced over 100 'Historical Minutes,' video tributes to important Canadians across many fields and specialties. One vignette, about Dr. Wilder Penfield, dramatically shows his discovery of the area in a patient's brain which triggers the smell of burnt toast and signals her seizures. Dr. Penfield is credited with this game-changing advance in neurological surgery and treatment. Quebec Globe and Mail correspondent Eric Andrew-Gee begins his excellent first book with this moment, determining to expand the record, telling the detailed story of the Montreal Neurological Institute — The Neuro — and the close relationship between 'the Chief,' Penfield, and his colleague and friend 'the Boss,' William Cone. Mackenzie Lad photo Eric Andrew-Gee Andrew-Gee's intricately researched and plotted paean to these surgical pioneers reads like a novel. It traces Cone and Penfield's decades of investigation, exploration and treatment of problems with humanity's most complicated and mysterious organ. The two met at Presbyterian Hospital in Philadelphia, finding 'a remarkable amount in common: they were both fatherless Midwesterners from medical families with dreams of transforming neurosurgery.' Collaborating in learning various aspects of the art — not yet a science — from practitioners around the world, Penfield and Cone eventually gain international fame. Penfield is hired by Montreal's Royal Victoria Hospital, on the condition they hire Cone as well. The development of their differing styles and areas of study, and the inevitable conflicts which their friendship covers, make for fascinating reading. Information about hospital conditions, and specific advances and inventions, as well as insight into the politics and culture of 20th-century Quebec intersperse the narrative. Andrew-Gee likens the pair to the 'two solitudes' of Hugh MacLennan's novel of the same name about language and relationships in Quebec and to the two halves of the brain. Penfield, known for intricate study of what different parts of the brain do, was the head of the Institute, focusing on memory and the effects and relief of epilepsy. More generally, he searched for the human mind residing in the physical brain. Cone was intent on patient care, from prepping to surgery to follow-up. He was obsessed with sterility (his father had died of typhoid fever caught from tainted water) and kept unhealthy hours on the job, all to the benefit of others. As in the 'Historical Minute,' Penfield was the face of the operation, publishing and receiving accolades for the work which they shared. 'Fortunately for the harmony of the institute,' notes Andrew-Gee, 'Cone didn't care about credit.' Cone was happiest when busy, and thrived when he served with the Canadian military medical corps at Hackwood, an English estate vacated by its baronial owner for the war effort. Cone, 'no longer Penfield's subordinate,' now led 'a hospital twice as big as The Neuro in the thick of history's most decisive conflict — and he was excelling.' Reunited in Montreal later in the war, the two continued to new heights in the treatment of brain injuries and illnesses, to international acclaim for Penfield. The Mind Mappers Andrew-Gee describes Cone's increasing symptoms of alienation, while still maintaining a breakneck schedule and his closeness to Penfield. Weekly A weekly look at what's happening in Winnipeg's arts and entertainment scene. Readers today will recognize clear signs of clinical depression, noticed but ignored at the time — ironically, in that centre of near-miraculous neurological discovery and development. After the much-foreshadowed tragic end of the collaboration, Andrew-Gee includes multiple tributes to Cone which demonstrate that 'he had shown… what it means to be a good doctor.' This chronicle of the friendship between Penfield and Cone demonstrates how relationships should work, acknowledging issues and weaknesses, while celebrating the positive and productive results of altruism and decency. Bill Rambo is a mostly retired teacher who lives in Landmark.
Cision Canada
3 days ago
- Cision Canada
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY Français
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY ® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy. "This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia," said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. "These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need." New longer-term follow-up data presented from the CASGEVY trials In SCD, 43/45 (95.6%) evaluable patients (those with at least 16 months of follow-up) were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months (VF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 84.9%, 99.5%). The mean duration of VOC-free was 35.0 months (range 14.4 to 66.2 months). All evaluable patients (45/45 [100%]) achieved freedom from in-patient hospitalization for severe VOCs for at least 12 consecutive months (HF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 92.1%, 100%), with a mean hospitalization-free of 36.1 months (range 14.5 to 66.2 months). In TDT, 54/55 (98.2%) evaluable patients (those with at least 16 months of follow-up) achieved transfusion-independence for at least 12 consecutive months with a weighted average hemoglobin (Hb) of at least 9 g/dL (TI12) in CLIMB-111 and CLIMB-131 combined (95% CI: 90.3%, 100%). The mean duration of transfusion independence was 40.5 months (range 13.6 to 70.8 months). The one evaluable patient who did not achieve TI12 has been transfusion free for 14.8 months. Iron removal therapy has been stopped for more than 6 months in 39/56 (69.6%) treated patients following infusion with CASGEVY, with sustained improvement in ferritin and liver iron content, suggesting that CASGEVY has the potential to correct ineffective erythropoiesis. Patients continue to demonstrate stable levels of fetal hemoglobin (HbF) and allelic editing. The safety profile of CASGEVY continues to be generally consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. Progress in bringing CASGEVY to patients Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales. In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending. Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or "sickled" red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Pr CASGEVY ® (exagamglogene autotemcel) Pr CASGEVY ® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Media: [email protected] orCanada: +1 647-790-1600orU.S.: 617-341-6992 SOURCE Vertex Pharmaceuticals (Canada) Inc.
